Recent discoveries demonstrate the importance of long noncoding RNA (lncRNA) in the regulation of multiple major processes impacting development, differentiation, and metastasis of hematological diseases through epigenetic mechanisms. In contrast to genetic changes, epigenetic modification does not modify genes but is frequently reversible, thus providing opportunities for targeted treatment using specific inhibitors. In this review, we will summarize the function and epigenetic mechanism of lncRNA in malignant hematologic diseases.
that noncoding RNAs play an important role in cell proliferation, differentiation, and body development, especially in malignant hematologic diseases by means of epigenetic mechanisms.
| NORMAL HEMATOPOIESIS
Studies have shown that lncRNAs play an important role during the normal hematopoietic development (Table S1 ).
Self-renewal of hematopoietic stem cells is partly sustained by developmental and environmental signals from their niche, which acts through developmentally conserved signaling pathways to promote proliferation while suppressing apoptosis and differentiation. 12, 13 During hematopoiesis, this self-renewal capability decreases as cell transition from multipotent stem cells to lineage-committed progenitors. LncRNAs have the capacity to modulate self-renewal of embryonic stem cells and act in the circuitry controlling the hematopoietic stem cell state.
14- 16 Venkatraman et al 17 Table S1 for detail.
Red blood cell production of erythropoiesis requires strict control of transcription factors, microRNAs, and lncRNAs in normal operation. [21] [22] [23] [24] [25] Hu et al identified lincRNA-EPS, an lncRNA with an abnormal expression and erythroid specificity. Mechanistically, lincRNA-EPS functions by regulating Pycard, a proapoptotic gene that activates caspase in apoptosis through encoding an adaptor protein. 26 LincRNA-EPS binds to the Pycard gene and recruits transcriptional repressor complexes to inhibit Pycard's transcription.
In addition, lncRNA Fas-antisense 1 (Fas-AS1 or Saf) also involves in the process of erythroid differentiation. These lncRNA-mediated promotion of the proliferation and erythroid differentiation may provide a new strategy to design the treatment of anemia and other related diseases. Therefore, the identification of new regulators for erythrocyte production is critical to find new opportunities for the treatment of erythrocyte diseases.
LncRNAs are also implicated in the regulation of myelopoiesis, Thus far, a handful of lncRNAs have been conclusively linked to cancers of the blood. We discuss these lncRNAs in this section, with an emphasis on their mechanism of action.
| Acute myeloid leukemia
Recent studies have demonstrated that lncRNAs contribute to the initiation, maintenance, and development of AML (Table S2) . Here, we emphasize their regulatory role in the pathogenesis of leukemia, with discussing the prognostic value of lncRNAs in AML patients.
HOTAIRM1 is a myeloid-specific long noncoding transcript.
HOTAIRM1 regulates myeloid differentiation genes such as CD11b
and CD18, and its knockdown impairs all-trans retinoic acid (ATRA)-induced granulocytic differentiation. 27 Newburger et al dem-
onstrate that HOTAIRM1 provides a regulatory link in myeloid maturation by modulating integrin-controlled cell cycle progression at the gene expression level. 33 Determination of the HOTAIRM1 level at diagnosis may provide relevant prognostic information in IR-AML and allow refinement of risk stratification based on common molecular markers. 34 Recently, they also reveal that PU.1 directly activates the expression of HOTAIRM1 through binding to the regulatory region of HOTAIRM1 during granulocytic differentiation.
Reduced PU.1 expression, rather than PML-RARα itself, results in the low expression of HOTAIRM1 in APL cells. 35 Chen et al show that HOTAIRM1 acts as a microRNA sponge in an autophagy pathway that includes miR-20a/106b, miR-125b, and their targets 36 ULK1, E2F1, and DRAM2.
NEAT1 is a widespread and abundant lncRNA. Although myeloid differentiation is usually considered to be dominantly controlled by highly myeloid-specific factors, NEAT1 has been reported to be responsive to ATRA and be essential for ATRA-mediated myeloid differentiation, suggesting that reduced expression of NEAT1 may play a role in the myeloid differentiation of APL cells. 37 This observation indicates that myeloid differentiation also requires commonly expressed long noncoding transcripts.
Besides, lncRNA PVT1 can promote the proliferation of myeloid leukemia in APL. 38 The oncogenic activity of PVT1 is closely related to c-MYC, whose overexpression can lead to hyperproliferation of cancer cells. Gain of PVT1 lncRNA expression was required for high MYC protein levels in the amplification of 8q24.21 amplified human cancer cells, which is observed in about 10% of AML patients. 39 On the one hand, PVT1 protects MYC from degradation by direct physical interaction. 39 On the other hand, PVT1 acts as a microRNA precursor for indirect regulation of MYC. 40 Hsa-miR-1204, which is derived from the exon 1b in the PVT1 locus, has been declared to be able to enhance the expression level of MYC. 40 Also, the coamplification of PVT1 and MYC informs us that it might be interesting to see the association or causal relationship of copy number of lncRNA with leukemogensis.
Another lncRNA should be mentioned. LncRNA urothelial carcinoma associated 1 (UCA1) has also been reported by Hughes et al to have the capability to modulate the proliferation of AML cells. 41 prognosis. 44, 45 Research has shown that microRNA-22 can regulate expression of MEG3 in AML. 46 Yao et al show that hypermethylation of the MEG3 promoter in AML may result from decreased TenEleven Translocation-2 (TET2) activity. 47 Indeed, MEG3 has been involved in regulation of the Rb and p16INK4a pathway and thus of cell proliferation in a variety of cancers. 48, 49 mechanism of action of BALR-6 in B-ALL. 64 Another lncRNA that affects B-ALL is ANRIL. Previous studies found that lncRNA ANRIL was overexpressed in prostate cancer tissues. 65 Recent studies have shown that ANRIL interacts with CBX7 of the PRC1 complex at the INK4b/ARF/INK4a locus and recruits PcG to regulate senescence and abnormal cell proliferation and the enhanced susceptibility to ALL. 65 Moreover, the influence of genetic variants at CDKN2A/B locus which comprises ANRIL enhances the risk of developing B-ALL. 66 As summarized in Table S3 , lncRNAs play an important role in tumorigenesis and may be used as biomarkers as well as therapy targets in human cancer.
| Chronic myeloid leukemia and chronic lymphocytic leukemia
Chronic myeloid leukemia (CML) is a hematological malignancy associated with translocations on chromosome 9 and chromosome 22 resulting in the formation of a Bcr-Abl heterozygous gene in more than 90% of CML cases. 67 Although abnormal expression of lncRNAs is associated with Bcr-Abl-mediated CML, the specific role of lncRNAs is unknown (Table S4) 
| Others
Studies indicate that lncRNAs are dysregulated in various devastating human diseases including cancer. Misregulation of lncRNAs has been correlated with poor patient outcome, prognosis, and cancer metastasis. In addition to the above hematological malignancies, lncRNAs play an important role in other blood diseases (Table S5) . 
